Diabetes Health in The News Podcast: FDA Approves Novo Nordisk’s Type 2 Diabetes Drug for Young Patients

Click above to listen!   There’s a new treatment for Type 2 diabetes that may be perfect for children. The FDA has recently approved Victoza injections as a treatment option to help lower blood sugar in children and adolescents ages 10-17. Designed to be used alongside exercise and diet, Victoza has been on the market since 2010 but was approved specifically for younger patients this

Read more

Once-Weekly Tanzeum for Type 2s Now Available

Tanzeum (albiglutide), a once-weekly injectable drug for type 2s from GSK (GlaxoSmithKline), USA is now available at pharmacies throughout the United States. The FDA approved U.S. sales on April 15. The drug is a glucagon-like peptide-1 receptor agonist (GLP-1) that can be used in conjunction with other type 2 drugs. GLP-1s work by inducing the pancreas to produce more insulin when blood sugar levels begin

Read more

Weekly Dulaglutide Performs Well in Comparison to Daily Liraglutide

A comparison of the effects on A1c between users of once-weekly dulaglutide (made by Eli Lilly and Company) and once-daily liraglutide (sold as Victoza from Novo Nordisk) shows that both drugs have very similar effects. Researchers at Ohio State University conducted a nine-country study of 599 type 2 patients, aged 18 years and older, with A1c’s between 7% and 10%, and taking at least 1,500

Read more

NBA Hall of Famer Dominique Wilkins: Has A Slam Dunk Formula for Diabetes

NBA Hall of Famer Dominique Wilkins, affectionately known as “The Human Highlight Film” has a few coaching tips for people with diabetes. Several years after retiring from the Atlanta Hawks, Dominique was diagnosed with type 2 diabetes. Once he stopped playing professional basketball, he stopped exercising and eating well.  Consequently, he started experiencing some common diabetes symptoms, blurry vision and frequent urination. Diabetes was not

Read more

FDA Backtracks Over GLP-1s’ Effects on Pancreas

The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer. GLP-1 drugs, which work by stimulating the body to produce insulin, include Bristol-Myers Squibb’s Byetta and Bydureon, Merck’s Januvia and Janumet, and Novo Nordisk’s Victoza. However,

Read more

Weekly Type 2 Drug to Be Delivered Via Needle Patch

A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system. The drug, now under development by Novo Nordisk, is semaglutide, a GLP-1 (glucagon-like peptide) receptor agonist that the company is hoping to introduce as a one-a-week therapy. GLP-1s stimulate the release of insulin while also

Read more

First-World Type 2 Drug Market to Reach $47 Billion by 2022

A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022. The firm, Decision Resources, says increased sales in the United States, Japan, France, Germany, Italy, Spain, and the United Kingdom, will come from both an increase in the type 2 patient population and the introduction of

Read more

Lilly Says Its New Injectible Outperforms Three Popular Diabetes Drugs

Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies. According to Lilly, dulaglutide, a GLP-1 analog, worked better to reduce A1c levels than metformin, Merck & Co.’s Januvia (sitagliptin),

Read more

Diabetes Health Type 2: Paula Deen: Cooking Up a New Life With Diabetes

Paula Deen, a celebrity Southern chef known for her unrestrained love of butter and sugar, is no stranger to the media. She received a flurry of bad press recently when she revealed that she had been diagnosed with type 2 diabetes three years earlier. Shortly thereafter, she became a spokesperson for Novo Nordisk’s Victoza. Following these developments, some critics said that she was a poor

Read more

Am I Doing the Right Thing?

Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma. Dear Diabetes Health: I am asthmatic and was diagnosed with diabetes two or three years ago. I am 61 and

Read more